Author

Jim West

Observed name: Jim W. West

Institution: CytomX Therapeutics (United States)

Observed institution: CytomX Therapeutics (United States)

ORCID: 0000-0001-6262-4554

Observed ORCID: 0000-0001-6262-4554

OpenAlex ID: A5049708441

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

2000 · Julia Parrish-Novak, Stacey R. Dillon, et al. · Nature · 1,251

2001 · Hal Blumberg, Darrell Conklin, et al. · Cell · 554

Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes

2002 · Julia Parrish-Novak, Wenfeng Xu, et al. · Journal of Biological Chemistry · 273

A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

2022 · Leila M. Boustany, Sherry L. LaPorte, et al. · Cancer Research · 70

Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2

2014 · Jason Sagert, Jim West, et al. · Cancer Research · 7

Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy.

2013 · Luc R. Desnoyers, Annie Yang, et al. · Cancer Research · 1

Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

2023 · Leila M. Boustany, Sherry L. LaPorte, et al.

Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

2023 · Leila M. Boustany, Sherry L. LaPorte, et al.

Supplementary Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

2023 · Leila M. Boustany, Sherry L. LaPorte, et al.

Works count: 9

Citation count: 2,156

H-index: 5

I10-index: 4